| Product Unit Size | Cost | Quantity | Stock |
|---|
GSK-2636771 is an inhibitor of the p110β isoform of PI3K. GSK-2636771 displays anticancer chemotherapeutic activity in PTEN-deficient cancers such as glioblastomas, prostate cancers, and endometrial cancers. This compound is currently in clinical trials.
| Cas No. | 1372540-25-4 |
|---|---|
| Purity | ≥98% |
| Formula | C22H22F3N3O3 |
| Formula Wt. | 433.42 |
| Chemical Name | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid |
| IUPAC Name | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4- ylbenzimidazole-4-carboxylic acid |
| Solubility | Soluble in DMSO(28mg/ml), and water with 1 eq. of base, insoluble in ethanol |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Weigelt B, Warne PH, Lambros MB, et al. PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.